Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above 200-Day Moving Average of $14.14

Assembly Biosciences, Inc. (NASDAQ:ASMB) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $14.14 and traded as high as $18.00. Assembly Biosciences shares last traded at $16.60, with a volume of 52,873 shares traded.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Thursday, June 20th.

Assembly Biosciences Trading Down 2.3 %

The company’s 50-day moving average price is $14.68 and its two-hundred day moving average price is $14.14.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.96) by $0.98. The firm had revenue of $8.53 million for the quarter, compared to analysts’ expectations of $5.96 million. As a group, sell-side analysts expect that Assembly Biosciences, Inc. will post -7.41 earnings per share for the current year.

Insiders Place Their Bets

In other Assembly Biosciences news, major shareholder Alexander Schornstein purchased 4,562 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The shares were purchased at an average cost of $12.29 per share, with a total value of $56,066.98. Following the completion of the purchase, the insider now owns 688,675 shares of the company’s stock, valued at approximately $8,463,815.75. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new position in Assembly Biosciences during the 2nd quarter worth approximately $6,421,000. Renaissance Technologies LLC boosted its stake in shares of Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 15,451 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 7,690 shares during the period. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.